847798-79-2

Basic information

• Product Name: 4-(4-morpholinyl)cyclohexanamine
• Synonyms: 4-(4-morpholinyl)cyclohexanamine;4-(4-Morpholinyl)-cyclohexanamine 2HCl
• CAS NO: 847798-79-2
• Molecular Formula: C10H20N2O
• Molecular Weight: 184.2786
• Mol File: 847798-79-2.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 4-(4-morpholinyl)cyclohexanamine(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(4-morpholinyl)cyclohexanamine(847798-79-2)
• EPA Substance Registry System: 4-(4-morpholinyl)cyclohexanamine(847798-79-2)

Safety Data

• Hazardous Substances Data: 847798-79-2(Hazardous Substances Data)

Upstream product

• 110-91-8 morpholine 
• 149506-79-6 4-(dibenzylamino)cyclohexanone 
• 2615-25-0 trans-1,4-cyclohexyldiamine 
• 558442-96-9 tert-butyl N-[4-(morpholin-4-yl)cyclohexyl]carbamate 
• 177906-48-8 trans-N-Boc-1,4-cyclohexanediamine 
• 755039-80-6 trans-dibenzyl-(4-morpholin-4-yl-cyclohexyl)-amine 
• 1246532-37-5 tert-Butyl trans-4-(4-morpholinyl)cyclohexylcarbamate 
• 100-00-5 4-chlorobenzonitrile 
• 10389-51-2 1-morpholino-4-nitrobenzene 

Relevant articles and documents

TREATMENT OF CDK4/6 INHIBITOR RESISTANT NEOPLASTIC DISORDERS

This invention is to methods for treating disorders involving abnormal cellular proliferation that have developed resistance to a selective CDK4/6 inhibitor.

HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF ABNORMAL CELLULAR PROLIFERATION

This invention is in the area of heterocyclic-based compounds for the treatment of disorders involving abnormal cellular proliferation, including but not limited to tumors and cancers.

COMPOUNDS AND THERAPEUTIC USES THEREOF

The invention relates to compounds, pharmaceutical compositions, and uses thereof, including therapeutic uses thereof, such as methods useful for treating cancer.

PYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS

The present invention relates to a compound of formula (VII)I, or a pharmaceutically acceptable salt or ester thereof, wherein: X is NR7; Y is O or N-(CH2)nR19; n is 1, 2 or 3; m is 1 or 2; R1 and Rs

2, 4-DIAMINOPYRIMIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CANCER

The present invention encompasses compounds of general formula (1) wherein Q and R1 to R4 are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or anomalous cell proliferation, and the

New pteridinones as PLK inhibitors

Disclosed compounds of general formula (1) wherein L, Q1, Q2, X, Y, Ra, Rb, Rc, R1, R2, R3 and R4 are defined as in claim 1, which are suitable for the trea

COMBINATIONS FOR THE TREATMENT OF DISEASES INVOLVING CELL PROLIFERATION

The present invention relates to a pharmaceutical composition for the treatment of diseases which involve cell proliferation. The invention also relates to a method for the treatment of said diseases, comprising co-administration of a compound 1 of Formula (I) wherein the groups L, R1, R2, R3, R4 and R5 have the meanings given in the claims and specification, optionally in form of its tautomers, racemates, enantiomers, diastereomers and the mixtures thereof and optionally in form of the pharmacologically acceptable acid addition salts, solvates, hydrates, polymorphs, physiologically functional derivatives or prodrugs thereof, and of an effective amount of an active compound 2 and/or co-treatment with radiation therapy, in a ratio which provides an additive and synergistic effect, and to the combined use of a compound 1 of Formula (I) and of an effective amount of an active compound 2 and/or radiotherapy for the manufacture of corresponding pharmaceutical combination preparations.

DIHYDROPTERIDINONES FOR THE TREATMENT OF CANCER DISEASES

The present invention relates to the use of a compound of general Formula (1), optionally in form of its tautomers, racemates, enantiomers, diastereomers and the mixtures thereof and optionally in form of the pharmacologically acceptable acid addition salts, solvates, hydrates, polymorphs, physiologically functional derivatives or prodrugs thereof, for the preparation of a pharmaceutical composition for the treatment of diseases characterized by abnormal cell proliferation in a human or non-human mammalian body by inhibition of polo like kinases as mitotic regulators.

Storage stable perfusion solution for dihydropteridinones

Disclosed are storage stable aqueous infusible or injectable solutions containing an active substance of general formula (I) wherein the groups L, R1, R2, R3, R4 and R5 have the meanings given in the claims and in the specification, and an amount of a physiologically acceptable acid or mixture of acids sufficient to dissolve the active substance and act as a stabiliser, optionally together with other formulating excipients suitable for parenteral administration, and a process for preparing the infusible or injectable solutions according to the invention.

PTERIDINONES USED AS PLK (POLO LIKE KINASE) INHIBITORS

The invention relates to compounds of general formula (1), wherein L, Q1, Q2, X, Y, Ra, Rb, Rc, R1, R2, R3, and R4 are defined as indicated in claim 1. Said